American Society for Biochemistry and Molecular Biology 2004 Annual Meeting
Tangles, Neurodegeneration, Plaques—p25 Does it All American Society for Biochemistry and Molecular Biology: 2004 Annual Meeting
6390 RESULTS
Sort By:
Tangles, Neurodegeneration, Plaques—p25 Does it All American Society for Biochemistry and Molecular Biology: 2004 Annual Meeting
News Summary from the 40th Annual Meeting of The American Society for Cell Biology Part II: News Summary from American Society for Cell Biology Meeting American Society for Cell Biology: 2000 Annual Meeting
American Society for Cell Biology 38th Annual Meeting: Tau Protein in Neurodegenerative Diseases American Society for Cell Biology 38th Annual Meeting: More About Tau American Society for Cell Biology 38th Annual Meeting: Novel Protein Binds to APP and Mi
Honolulu: Potential New Gene on the ALS List American Society for Human Genetics Annual Meeting
Meeting Report: American Society for Neurochemistry (22-26 June 2002) American Society for Neurochemistry
Exploring Genome Fragmentation in Neurodegeneration Up-and-Coming ALS Mice Leave Scientists ConFUSed Does ALS Gene Police RNA, Keep Strands From Entangling? Does New Amyloid Protein Lend Tau a Hand? Keystone Symposium: New Frontiers in Neurodegenerative D
Keystone: Death Receptor Ligand—New Role for APP, New Model for AD? Keystone: Partners in Crime—Do Aβ and Prion Protein Pummel Plasticity? Keystone: Longevity, Insulin-like Growth Factor Signaling, and Aβ Toxicity Keystone: Pulse-Chasing AD Biomarkers, Sn
DC: CAMD Convenes Stakeholders to Reform Alzheimer’s Trials DC: Standard Data—Music to Regulators’ Ears DC: Shared Pain Is Lessened—Open-Trial Data Gain AD Model DC: Biomarkers, Parkinson’s—CAMD Needs All Hands on Deck Trial failure after trial failure: D
London: Europe-U.S. Regulators Mull Prevention Trial in Familial AD London: What, No Argument? Speakers Agree on Trials for Familial AD London: What Regulators Say About Trials in Familial AD London: Families Talk About Treatment Trials In November 2010,
Bethesda: Dawn of the Epigenetics Era Bethesda: The Methylated Brain Bethesda: "Ome" Sweet "Ome"—Epigenome Joins Genome, Proteome Epigenetics, the "software" that interprets information stored in the DNA "hardware,"
Scientists Strategize With Regulators for Frontal Assault on FTD Toward FTD Therapeutic Trials: Diagnosis Firm, Outcomes Still Soft Case Studies Crystallize Trial Ideas at FTD Conference Take It From the Agency: First FTD Drug May Be an Orphan For FTD Dru
Phoenix: Vision of Shared Prevention Trials Lures Pharma to Table Phoenix: Can Alzheimer’s Prevention Initiative Break a Catch-22? Phoenix: Trials in Colombia and the U.S. for Those at Highest Risk? Phoenix: For Shared Prevention Trials, Devil Is in the D
Tall Science at Small Retreat: Dispatch from Germany’s Eibsee Oligomers Abound, But Where’s the Seed? γ-Secretase: Ins and Outs of a Voracious Membrane Protein Grinder First Look at the Secretase, New Kid on the Block Assembly, Traffic Escorts, Fats All C
DIAN Dispatch From Hawaii: After Slow Start, Network Is Humming DIAN Dispatch from Hawaii: Glimpse at Data, Push for Trials The DIAN represents a bold attempt at pushing Alzheimer's clinical research squarely into the preclinical phase. It enrolls ad
Mesulam Awarded Potamkin Prize Three’s Company: Florbetaben Approved, Excludes AD Diagnosis PET Tracers Enlighten at Neurology Conference Blood Patterns: Prowling for Alzheimer’s Clues in Plasma Tau imaging of patients with different kinds of dementia and
No filters selected